Share

January 25, 2022; 98 (4) Research Article

Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis

The BeatMG Study

Richard J. Nowak, Christopher S. Coffey, Jonathan M. Goldstein, Mazen M. Dimachkie, Michael Benatar, John T. Kissel, Gil I. Wolfe, Ted M. Burns, Miriam L. Freimer, Sharon Nations, Volkan Granit, A. Gordon Smith, David P. Richman, Emma Ciafaloni, Muhammad T. Al-Lozi, Laura Ann Sams, Dianna Quan, Eroboghene Ubogu, Brenda Pearson, Aditi Sharma, Jon W. Yankey, Liz Uribe, Michael Shy, Anthony A. Amato, Robin Conwit, Kevin C. O'Connor, David A. Hafler, Merit E. Cudkowicz, Richard J. Barohn, on behalf of the NeuroNEXT NN103 BeatMG Study Team
First published December 2, 2021, DOI: https://doi.org/10.1212/WNL.0000000000013121
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
1137

Share

Article Information

vol. 98 no. 4 e376-e389
DOI: 
https://doi.org/10.1212/WNL.0000000000013121
PubMed: 
34857535
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received July 1, 2020
  • Accepted in final form November 19, 2021
  • First Published December 2, 2021.

Article Versions

Copyright & Usage: 
© 2021 American Academy of Neurology

Author Disclosures

    1. Richard J. Nowak, MD,
    2. Christopher S. Coffey, PhD,
    3. Jonathan M. Goldstein, MD,
    4. Mazen M. Dimachkie, MD,
    5. Michael Benatar, MD, PhD,
    6. John T. Kissel, MD,
    7. Gil I. Wolfe, MD,
    8. Ted M. Burns, MD,
    9. Miriam L. Freimer, MD,
    10. Sharon Nations, MD,
    11. Volkan Granit, MD,
    12. A. Gordon Smith, MD,
    13. David P. Richman, MD,
    14. Emma Ciafaloni, MD,
    15. Muhammad T. Al-Lozi, MD,
    16. Laura Ann Sams, MD,
    17. Dianna Quan, MD,
    18. Eroboghene Ubogu, MD,
    19. Brenda Pearson, BS,
    20. Aditi Sharma, MBBS,
    21. Jon W. Yankey, MS,
    22. Liz Uribe, MS,
    23. Michael Shy, MD,
    24. Anthony A. Amato, MD,
    25. Robin Conwit, MD,
    26. Kevin C. O'Connor, PhD,
    27. David A. Hafler, MD,
    28. Merit E. Cudkowicz, MD,
    29. Richard J. Barohn, MD;
    30. on behalf of the NeuroNEXT NN103 BeatMG Study Team
  1. Richard J. Nowak, MD,
    2. Scientific Advisory Boards:

    1. (1) Ra Pharma, (2) Alexion, (3) argenx, (4) Immunovant, (5) Momenta

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Grifols, (2) Alexion

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Alexion, (2) Grifols, (3) Ra Pharma, (4) Momenta, (5) Immunovant, (6) CSL Behring

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1) While drug/placebo were provided by Genentech through an investigator-initiated trial agreement with Dr. Nowak, they were not involved in trial design, implementation or data analysis. (2) Dr. Nowak is Global Principal Investigator for a phase 3 trial in myasthenia gravis through a research agreement(Viela Bio, a part of Horizon Therapeutics).

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Alexion, (2) Genentech, (3) Grifols, (4) Ra Pharma, (5) argenx, (6) Momenta, (7) Immunovant, (8) Viela Bio

    Research Support, Government Entities:

    1. (1) National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health under award number U01NS084495, PI, 2013-2019

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Myasthenia Gravis Foundation of America (MGFA)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Christopher S. Coffey, PhD,
    3. Scientific Advisory Boards:

    1. (1) Several NIH Sponsored DSMBs

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Michael J Fox Foundation for Parkinson's Research, Funding for travel to meetings

    Editorial Boards:

    1. (1) Clinical Trials, Associate Editor (2) Trials, Associate Editor (3) Stroke, Statistical Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH U24 NS112873, Co-PI, 2019-2023 (2) NIH U01 NS077352, Principal Investigator, 2011-2023 (3) NIH R25 HL131467, Co-Investigator, 2016-2022 (4) NIH U01 NS096767, Principal Investigator (Subcontract), 2016-2022 (5) NIH U01 NS095388, Principal Investigator (Subcontract), 2017-2022 (6) NIH U01 AR070498, Principal Investigator (Subcontract), 2017-2022 (7) NIH U01 NS114001, Principal Investigator (Subcontract), 2019-2022

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) The Michael J Fox Foundation for Parkinson's Research

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Jonathan M. Goldstein, MD,
    4. Scientific Advisory Boards:

    1. 1.Advisory board Alexion pharmaceutical

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NINDS, U01NS084495, Investigator, 2013-2019

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Mazen M. Dimachkie, MD,
    5. Scientific Advisory Boards:

    1. Dr. Dimachkie serves or recently served as a consultant for Amazentis, ArgenX, Catalyst, Cello, Covance/Labcorp, CSL-Behring, EcoR1, Janssen, Kezar, Momenta, NuFactor, Octapharma, RaPharma/UCB, Roivant Sciences Inc, RMS Medical, Sanofi Genzyme, Shire Takeda, Scholar Rock, Spark Therapeutics, Third Rock and UCB Biopharma. Dr. Dimachkie received research grants or contracts from Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, Corbus, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Kezar, Mitsubishi Tanabe Pharma, MDA, NIH, Novartis, Octapharma, Orphazyme, Ra Pharma/UCB, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark, UCB Biopharma, Viromed/Healixmith & TMA.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Dr. Dimachkie serves or recently served as a consultant for Amazentis, ArgenX, Catalyst, Cello, Covance/Labcorp, CSL-Behring, EcoR1, Janssen, Kezar, Momenta, NuFactor, Octapharma, RaPharma/UCB, Roivant Sciences Inc, RMS Medical, Sanofi Genzyme, Shire Takeda, Scholar Rock, Spark Therapeutics, Third Rock and UCB Biopharma. Dr. Dimachkie received research grants or contracts from Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, Corbus, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Kezar, Mitsubishi Tanabe Pharma, MDA, NIH, Novartis, Octapharma, Orphazyme, Ra Pharma/UCB, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark, UCB Biopharma, Viromed/Healixmith & TMA.

    Editorial Boards:

    1. Journal of Clinical Neuromuscular Disease; Editorial Board Member Reviewer: Frontiers in Neurology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr. Dimachkie serves or recently served as a consultant for Amazentis, ArgenX, Catalyst, Cello, Covance/Labcorp, CSL-Behring, EcoR1, Janssen, Kezar, Momenta, NuFactor, Octapharma, RaPharma/UCB, Roivant Sciences Inc, RMS Medical, Sanofi Genzyme, Shire Takeda, Scholar Rock, Spark Therapeutics, Third Rock and UCB Biopharma. Dr. Dimachkie received research grants or contracts from Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, Corbus, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Kezar, Mitsubishi Tanabe Pharma, MDA, NIH, Novartis, Octapharma, Orphazyme, Ra Pharma/UCB, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark, UCB Biopharma, Viromed/Healixmith & TMA.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr. Dimachkie received research grants or contracts or educational grants from Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, Corbus, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Kezar, Mitsubishi Tanabe Pharma, MDA, NIH, Novartis, Octapharma, Orphazyme, Ra Pharma/UCB, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark Therapeutics, UCB Biopharma / RaPharma, Viromed/Healixmith & TMA. Dr. Dimachkie received research grants or contracts from Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, Corbus, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Kezar, Mitsubishi Tanabe Pharma, MDA, NIH, Novartis, Octapharma, Orphazyme, Ra Pharma/UCB, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark, UCB Biopharma, Viromed/Healixmith & TMA.

    Research Support, Government Entities:

    1. NIH FDA-OOPD

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Michael Benatar, MD, PhD,
    6. Scientific Advisory Boards:

    1. (1) Viela Bio (2) Immunovant (3) Alexion (4) UCB (5) SANOFI (6)Biogen (7) Denali (8) Orphazyme (9) Novartis (10) Alector

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. US Provisional Patent Application. Determining onset of amyotrophic lateral sclerosis

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) National Institutes of Health (U24 NS107376), PI, 2018-2023 (2 National Institutes of Health (U54 NS092091), PI, 2014-2024 (3) National Institutes of Health (U01 NS107027), PI, 2018-2023 (4) National Institutes of Health (R01 NS205479), PI, 2018-2023 (5) National Institutes of Health (R21 NS111275), Co-I, 2019-2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) ALS Association (16-TACL-242) (2) MDA (376132) (3) Target ALS

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. John T. Kissel, MD,
    7. Scientific Advisory Boards:

    1. Member of Data Safety Monitoring Board for NIH NeuroNext Study $0-$4,999

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. Oxford Press: 2004-present

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Gil I. Wolfe, MD,
    8. Scientific Advisory Boards:

    1. (1)UCB/Ra Scientific Advisory Board (2)ArgenX Scientific Advisory Board (3)BPL Scientific Advisory Board (4)Orphazyme DSMB (5)Alexion Scientific Advisory Board

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Grifols speaker honoraria (2) Alexion speaker honoraria

    Editorial Boards:

    1. RRNMF Neuromuscular Journal, Editorial Board member, 2020-2021

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. As above under #3

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) UCB/Ra Pharma for research support (2) Immunovant for research support (3) ArgenX for research support (4) Roche for research support

    Research Support, Government Entities:

    1. PCORI: 1609-35953, PROMISE-MG: Prospective multicenter observational cohort study of comparative effectiveness of disease-modifying treatments for myasthenia gravis (Site Principal Investigator, PI D. Sanders). 1/1/18- 12/31/19, Per patient reimbursement $3600.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. MG Foundation of America

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Ted M. Burns, MD,
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Miriam L. Freimer, MD,
    10. Scientific Advisory Boards:

    1. Commercial: Alexion, ARGENX, UCB

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Commercial: alexion Amicus Alnylum Orphyzyme Fulcrum UCB Takeda

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Sharon Nations, MD,
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Volkan Granit, MD,
    12. Scientific Advisory Boards:

    1. (1)Myasthenia Gravis Foundation of America (2)Argenx (3)Alexion Pharmaceuticals (4)Immunovant Sciences GMBH

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1)Argenx (2)Immunovant Sciences GMBH

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. (1) McAloon&Friedman, Expert Witness, 2018 (2) Jackson Kelly PLLC, Expert Witness, 2019

  12. A. Gordon Smith, MD,
    13. Scientific Advisory Boards:

    1. Lexicon DSMB NIH DSMB Disarm Therapeutics Study Steering Committee Co-Chair Eidos DSMB

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Continuum Editorial Board Annals of Clinical and Translational Neurology Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Merz (2) Disarm Therapeutics (3) Alexion (4) Argenx

    Speakers' Bureaus:

    1. (1) Alexion

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) DK064814 PI 2004-2020 NIDDK (2) U01NS0953880 PI 2017-2021 NINDS

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  13. David P. Richman, MD,
    14. Scientific Advisory Boards:

    1. Cabaletta Bio

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Cabaletta bio Sponsored Research Agreement

    Research Support, Government Entities:

    1. NINDS, 1 R21 NS104516-01, Principal Investigator, 7/1/18- 6/30/21.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Myasthenia Gravis Foundation of America

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  14. Emma Ciafaloni, MD,
    15. Scientific Advisory Boards:

    1. Sarepta Avexis Stronbridge NS Pharma Biogen Santhera PTC Alexion Wave Sanofi Scholar Rock

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. MedLink

    Patents:

    1. NONE

    Publishing Royalties:

    1. Oxford Press

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Center Disease Control Prevention:

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Sarepta, PTC, Santhera, Orphazyme: clinical trial support

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  15. Muhammad T. Al-Lozi, MD,
    16. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  16. Laura Ann Sams, MD,
    17. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  17. Dianna Quan, MD,
    18. Scientific Advisory Boards:

    1. Alnylam Pharmaceuticals

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Pfizer, travel to PI meeting (commercial entity) AANEM, speaker honoraria

    Editorial Boards:

    1. Neurology Today, Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. Diabetic Neuropathy, eMedicine, current online, royalties Ocular Myasthenia Gravis, UpToDate, current online, royalties

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. IngenioRx

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Alnylam Pfizer Ionis Cytokinetics Argenx Momenta Alexion VielaBio

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  18. Eroboghene Ubogu, MD,
    19. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. Ubogu EE. Neurology Oral Boards Review: A Concise and Systematic Approach to Clinical Practice, Humana Press, Totowa, August 2005. ISBN: 1-58829-654-7 (paperback version), ISBN: 1-59259-984-2 (e-Book version). Cardona AE, Ubogu EE (eds.) Chemokines: Methods and Protocols, Methods in Molecular Biology, Springer Science + Business Media, New York 2013. ISBN: 978-1-62703-425-8 (hardback version), ISBN: 978-1-62703-426-5 (eBook), DOI: 10.1007/978-1-62703-426-5.

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1) Commercial entity: Latigo Biotherapeutics (specialist advice on the blood-nerve barrier permeability and neuropathic pain therapeutics).

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Argenx BVBA, (2) Genzyme Corporation

    Research Support, Government Entities:

    1. (1) NIH/NINDS, R21 NS109644-01A1, Principal Investigator, 2019-2021, (2) NIH/NINDS, R21 NS113033-01A1, Principal Investigator, 2020-2022, (3) NIH/NINDS, R01 NS116704-01, Subcontract Principal Investigator/ Co-Investigator, 2020- 2024, (4) NIH/NINDS, U01 NS095388, Site Principal Investigator, 2018-2023, (5) NIH/NINDS, R01NS090083–06, Site Principal Investigator, 2016-2020

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. (1) SV40 Large T-antigen immortalized human endoneurial endothelial cell line, Baylor Licensing Group, 2021

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  19. Brenda Pearson, BS,
    20. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  20. Aditi Sharma, MBBS,
    21. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  21. Jon W. Yankey, MS,
    22. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  22. Liz Uribe, MS,
    23. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Everest Clinical Research, Senior Biostatistician 1, 2 years

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  23. Michael Shy, MD,
    24. Scientific Advisory Boards:

    1. (1) Charcot Marie Tooth Association-Non Profit (2) Muscular Dystrophy Association (MDA)-Non Profit

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neuromuscular Disorders, Editorial Board Muscle and Nerve, Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Alnylam Pharmaceuticals - Consultant (2) Mitochondria in Motion-Consultant (3) Inflectis BioSci - Consultant (4) Neurogene - Consultant (5) Applied Therapeutics - (Consultant)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NINDS/Office of Rare Disease/NCATS

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Muscular Dystrophy Association; (2) Charcot Marie Tooth Association

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  24. Anthony A. Amato, MD,
    25. Scientific Advisory Boards:

    1. Medical Advisory Board for Orphazyme, Argenx, Ra Pharma, Johnson and Johnson

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Associate Editor for Neurology

    Patents:

    1. NONE

    Publishing Royalties:

    1. Amato AA, Russell J. Neuromuscular Disease (2nd Ed). New York: McGraw-Hill, 2016 Harrisons Principles of Internal Medicine, New York, McGraw-Hill, 2021 (in-press) Up-to-Date

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Medical Consultant for Best Doctors

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Expert witness for defendant in medical malpractice cases

  25. Robin Conwit, MD,
    26. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  26. Kevin C. O'Connor, PhD,
    27. Scientific Advisory Boards:

    1. Commercial entity - Alexion, now part of AstraZeneca

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Commercial entities: Consultant/advisor for Alexion Pharmaceuticals, Takeda, and for Roche.

    Speakers' Bureaus:

    1. Received speaking fees from Alexion and Viela Bio, now part of Horizon Therapeutics.

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Received research support from Ra Pharma and is a consultant and equity shareholder of Cabaletta Bio. KO’C is the recipient of a sponsored research subaward from the University of Pennsylvania, the primary financial sponsor of which is Cabaletta Bio. Received research support from Ra Pharma, now a part of UCB Pharma, and Alexion, now part of AstraZenca, and Viela Bio, now part of Horizon Therapeutics.

    Research Support, Government Entities:

    1. Supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) through awards R01-AI114780 and R21-AI142198, NIH through the Rare Diseases Clinical Research Consortia of the NIH (Award Number U54-NS115054)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1. Guthy Jackson Charitable Organization 2. A Neuromuscular Disease Research Program award from the Muscular Dystrophy Association (MDA) under award number MDA575198.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. Equity shareholder of Cabaletta Bio.

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  27. David A. Hafler, MD,
    28. Scientific Advisory Boards:

    1. D.A.H. has received research funding from Bristol-Myers Squibb, Novartis, Sanofi, ARCUS, and Genentech. He has been a consultant for Bayer Pharmaceuticals, Bristol Myers Squibb, Compass Therapeutics, EMD Serono, Genentech, Juno therapeutics, Novartis Pharmaceuticals, Proclara Biosciences, Sage Therapeutics, and Sanofi Genzyme.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. D.A.H. has received research funding from Bristol-Myers Squibb, Novartis, Sanofi, ARCUS, and Genentech. He has been a consultant for Bayer Pharmaceuticals, Bristol Myers Squibb, Compass Therapeutics, EMD Serono, Genentech, Juno therapeutics, Novartis Pharmaceuticals, Proclara Biosciences, Sage Therapeutics, and Sanofi Genzyme.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Funded as PI or Co-PI by NIH grants (1) P01AI073748, 2008- 2013, (2)P01 AI045757,2013-2018, (3) R01 NS049477, 2010- 2015, (4) R01 AI091568, 2010-2015, (5) U19 AI089992, 2010- 2022,(6) P01 AI039671, 2010-2022, (7) R25 NS079193, 2012- 2022, (8) U01 AI02011, 2012-2017, (9) U01NS084495-01A1, 2013-2017, Funded as Co-PI by Department of the Army grant # MS110275, 2012-2013

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Funded as PI by (1) National Multiple Sclerosis Society grant # CA 1061-A-18, 2009-2019, (2) Nancy Taylor Foundation grant, 2011-2013

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  28. Merit E. Cudkowicz, MD,
    29. Scientific Advisory Boards:

    1. Lilly DSMB

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neurotherapeutics editorial board JAMA Neurology editorial board

    Patents:

    1. Metabolomics in ALS - patent MIR 155 inhibitor - patent

    Publishing Royalties:

    1. UptoDate MND chapter

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Cytokinetics, Biogen, Orion, ImmunityPharm, Biohaven, Avexis, Revalesio, MT Pharma

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NINDS - U01 NeuroNEXT

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Muscular dystrophy association, als association, als finding a cure foundation, ALS One

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  29. Richard J. Barohn, MD;
    30. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Journal of Clinical Neuromuscular Disease, Associate Editor, 2002-Present (2) RRNMF Neuromuscular Journal, editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis, (2) Sanofi/Genzyme, (3) Biomarin, (4) Ionis, (5) Teva, (6) Cytocenetics, (7) Eli-Lily

    Research Support, Government Entities:

    1. (1) NIH/NCATS, UL1 TR000001, PI, 2011–2018, (2) FDA OPD, RO1FD003739, PI, 2012-2017, (3) NIH/NINDS, 1U10NS077356, PI, 2011-2018, (4) NIH, U54TR001137, Co-Investigator, 2014-2019, (5) PCORI, CER-1306-02496, PI, 2014-2018, (6) FDA OPD, RO1FD003937, PI, 2016-2019, (7) PCORI, CDRN-1501-26643, Co- Investigator, 2015-2018.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  30. on behalf of the NeuroNEXT NN103 BeatMG Study Team
    1. From the Department of Neurology (R.J.N., A.S., K.C.O., D.A.H.), Yale University School of Medicine, New Haven, CT; Clinical Trials Statistical & Data Management Center (C.S.C., B.P., J.W.Y., L.U.) and Department of Neurology (A.S.), University of Iowa, Iowa City; Department of Neurology (J.M.G.), Hospital for Special Surgery, New York, NY; Department of Neurology (M.M.D., R.J.B.), Kansas University School of Medicine, Kansas City; Department of Neurology (M.B., V.G.), University of Miami Miller School of Medicine, FL; Department of Neurology (J.T.K., M.L.F.), The Ohio State University Wexner Medical Center, Columbus; Department of Neurology (G.I.W.), University at Buffalo Jacobs School of Medicine & Biomedical Sciences, Buffalo, NY; Department of Neurology (T.M.B.), University of Virginia School of Medicine, Charlottesville; Department of Neurology (S.N.), University of Texas Southwestern Medical School, Dallas; Department of Neurology (V.G.), Albert Einstein College of Medicine, Bronx, NY; Department of Neurology (A.G.S.), University of Utah School of Medicine, Salt Lake City; Department of Neurology (D.P.R.), University of California Davis School of Medicine, Sacramento; Department of Neurology (E.C.), University of Rochester School of Medicine & Dentistry, NY; Department of Neurology (M.T.A.-L.), Washington University School of Medicine, St. Louis, MO; Department of Neurology (L.A.S.), University of Cincinnati College of Medicine, OH; Department of Neurology (D.Q.), University of Colorado School of Medicine, Aurora; Department of Neurology (E.U.), The University of Alabama at Birmingham School of Medicine; Department of Neurology (M.S.), Carver College of Medicine, University of Iowa, Iowa City; Department of Neurology (A.A.A.), Brigham and Women's Hospital, Boston, MA; Division of Clinical Research (R.C.), National Institute of Neurological Disorders and Stroke, Rockville, MD; Department of Neurology (M.E.C.), Massachusetts General Hospital, Boston; and Department of Neurology (R.J.B.), University of Missouri, Columbia.
    1. Correspondence
      Dr. Nowak richard.nowak{at}yale.edu
    View Full Text

    Article usage

    Article usage: December 2021 to April 2022

    AbstractFullPdfSource
    Dec 202120490140Highwire
    Jan 20227781592317Highwire
    Feb 202254923296Highwire
    Mar 202218860207Highwire
    Apr 202211390177Highwire

    Cited By...

    Disputes & Debates: Rapid online correspondence

    No comments have been published for this article.
    Comment

    REQUIREMENTS

    If you are uploading a letter concerning an article:
    You must have updated your disclosures within six months: http://submit.neurology.org

    Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

    If you are responding to a comment that was written about an article you originally authored:
    You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
    and apply to letter.

    Submission specifications:

    • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
    • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
    • Submit only on articles published within 6 months of issue date.
    • Do not be redundant. Read any comments already posted on the article prior to submission.
    • Submitted comments are subject to editing and editor review prior to posting.

    More guidelines and information on Disputes & Debates

    Compose Comment

    More information about text formats

    Plain text

    • No HTML tags allowed.
    • Web page addresses and e-mail addresses turn into links automatically.
    • Lines and paragraphs break automatically.
    Author Information
    NOTE: The first author must also be the corresponding author of the comment.
    First or given name, e.g. 'Peter'.
    Your last, or family, name, e.g. 'MacMoody'.
    Your email address, e.g. higgs-boson@gmail.com
    Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
    Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
    Publishing Agreement
    NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

    Vertical Tabs

    You May Also be Interested in

    Back to top
    Advertisement

    Related Articles

    • No related articles found.

    Alert Me